<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03952572</url>
  </required_header>
  <id_info>
    <org_study_id>CSPC-DMS-LY-02</org_study_id>
    <nct_id>NCT03952572</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma</brief_title>
  <official_title>Open-label Multi-center Randomized Non-inferiority Study to Compare Efficacy and Safety of Pegylated Liposomal Doxorubicin Versus Doxorubicin for Newly Diagnosed Peripheral T-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective of the study is to compare the efficacy and safety of CDOP versus CHOP for
      newly diagnosed peripheral T-cell lymphoma (PTCL).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a open-label, multi-center, randomized, non-inferiority study to compare efficacy and
      safety of CDOP with standard CHOP regimen in patients with previously untreated PTCL. Study
      subjects are patients with histologically proven newly diagnosed PTCL. Patients are
      randomized 1:1 to receive either cyclophosphamide, pegylated liposomal doxorubicin,
      vincristine and prednisone (CDOP) administered in 3 week cycles for 6 cycles or
      cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered in 3 week
      cycles for 6 cycles.This study is divided into three phases: screening phase, treatment phase
      and follow-up phase. Patients will receive study drug(s) for up to 6 cycles, or until
      unacceptable toxicity will develop or progression or voluntary withdrawal.Adverse event of
      every treatment cycle will be recorded.Therapy efficacy will be evaluated after finishing 2
      cycles, 4cycles and finishing 6 cycles therapy. Patients will be followed until disease
      progression, died or 2 years from the last patient randomized.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 10, 2019</start_date>
  <completion_date type="Anticipated">April 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>2 years</time_frame>
    <description>complete response (CR) and partial response (PR) rates, using the standard response criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>2 years</time_frame>
    <description>from date of inclusion to date of progression, relapse, or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years</time_frame>
    <description>from the date of inclusion to date of death, irrespective of cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac toxicity</measure>
    <time_frame>2 years</time_frame>
    <description>cardiotoxity Congestive heart failure with clinical symptoms, or no symptoms but an abnormal LVEF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>2 years</time_frame>
    <description>any unfavorable and unintended sign , symptom, or disease temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">244</enrollment>
  <condition>Peripheral T-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>CDOP regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cyclophosphamide, pegylated liposomal doxorubicin, vincristine and prednisone (CDOP) administered in 3 week cycles for 6 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHOP regimen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered in 3 week cycles for 6 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>750mg/m² ivgtt on day 1</description>
    <arm_group_label>CDOP regimen</arm_group_label>
    <arm_group_label>CHOP regimen</arm_group_label>
    <other_name>CTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegylated liposomal doxorubicin</intervention_name>
    <description>40mg/m² ivgtt on day 1</description>
    <arm_group_label>CDOP regimen</arm_group_label>
    <other_name>PLD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>1.4mg/m²(Maximum 2 mg) ivgtt on day 1</description>
    <arm_group_label>CDOP regimen</arm_group_label>
    <arm_group_label>CHOP regimen</arm_group_label>
    <other_name>VCR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Prednisone100mg/m² po on day1-5</description>
    <arm_group_label>CDOP regimen</arm_group_label>
    <arm_group_label>CHOP regimen</arm_group_label>
    <other_name>PED</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>50mg/m² ivgtt on day 1</description>
    <arm_group_label>CHOP regimen</arm_group_label>
    <other_name>DOX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with histologically proven untreated peripheral T-cell lymphoma (include PTCL
             not otherwise specified（PTCL-NOS）, angioimmunoblastic T cell lymphoma（AITL）,
             anaplastic large cell lymphoma（ALCL）and other peripheral T-cell lymphoma(except NK/T
             cell lymphoma);

          2. Males and females of 18 years of age to 75 years of age.

          3. Eastern Cooperative Oncology Group (ECOG) performance status 0- 2.

          4. At least 1 single size measurable lesions, CT or PET-CT scan shows more than 15mm.

          5. Estimated survival time ≥ 6 months

          6. Liver function: transaminases≤3×ULN，or transaminases≤3×ULN for liver metastasis，total
             bilirubin ≤1.5ULN，or total bilirubin ≤2.5ULN for Gilbert's syndrome

          7. Renal function: serum creatinine ≤1.5×ULN or creatinine clearance ≥ 60 ml / min (
             standard Cockcroft-Gault formula);

          8. peripheral hemogram: WBC≥3.0×10^9/L, ANC≥1.5×10^9/L, Hb≥90g/L, PLT≥75×10^12/L.

          9. Cardiac ultrasound LVEF≥55%;

         10. New York Heart Association (NYHA) heart function classification is I grade;

         11. sign informed consent.

        Exclusion Criteria:

          1. Patients with primary or secondary central nervous system lymphoma；

          2. Serious heart disease, including but not limited to:

        1)Significant ventricular arrhythmia or high degree atrioventricular block (Mobitz II or
        third degree atrioventricular block); 2) unstable angina; 3) clinically significant heart
        valve disease; 4) Electrocardiogram shows transmural myocardial infarction; 5)
        Uncontrollable hypertension; 3. interstitial pneumonia, allergic asthma or severe allergic
        medical history; 4.Patients with other malignancies in the past or now (except basal cell
        carcinoma, squamous-cell carcinoma or carcinoma in situs of cervix that has been adequately
        treated), 5.HIV antibody positivity; 6.Acute or chronic active hepatitis B (HBsAg
        positivity, HBV DNA negative acceptable), acute or chronic active hepatitis C (HCV antibody
        negatively acceptable; HCV antibody positivity, HCV RNA negative acceptable) 7.Pregnancy or
        lactation period 8.Patients with Organ transplantation 9.Patients with serious uncontroled
        acute infection 10.High doses of hormones are contraindicated, such as uncontrolled
        hyperglycemia, stomach ulcers or Mental illness, etc.

        11.Patients with severe neurological or psychiatric history, including dementia or epilepsy
        12.The researchers considered that patients are not suitable for the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Zhu, PHD</last_name>
    <role>Study Chair</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jun Zhu, PHD</last_name>
    <phone>0086-10-88196115</phone>
    <email>zj@bjcancer.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuqin Song, PHD</last_name>
    <phone>0086-10-88196115</phone>
    <email>songyuqin622@sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking University Cancer Hospital &amp; Institute</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Zhu</last_name>
      <email>zj@bjcancer.org</email>
    </contact>
    <contact_backup>
      <last_name>Yuqin Song</last_name>
      <email>songyuqin622@sina.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yuqin Song</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 10, 2019</study_first_submitted>
  <study_first_submitted_qc>May 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2019</study_first_posted>
  <last_update_submitted>May 15, 2019</last_update_submitted>
  <last_update_submitted_qc>May 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Jun Zhu</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

